Altria
MO
$70.19
+0.86%
Altria Group, Inc. is a leading tobacco company in the United States, operating in the Consumer Defensive sector with a core business focused on cigarettes, smokeless tobacco, and cigars through subsidiaries like Philip Morris USA and U.S. Smokeless Tobacco. The company is a dominant market leader, holding the top position in U.S. cigarettes and smokeless tobacco, anchored by its flagship Marlboro brand which commands a 40% market share. The current investor narrative is dominated by the tension between its high-yield, cash-generative legacy tobacco business and the ongoing challenges and investments in its smoke-free transformation, including its 2023 acquisition of NJOY and its stake in cannabis firm Cronos, as it navigates secular declines in combustible products.…
MO
Altria
$70.19
Related headlines
Investment Opinion: Should I buy MO Today?
Rating: Hold. The core thesis is that Altria is a high-yield, cash-generative defensive stock trading at a fair valuation, but its severe leverage and secular headwinds cap upside potential, making it suitable only for income-oriented investors with a high risk tolerance.
Supporting this view, the stock trades at a reasonable forward P/E of 12.2x, a discount to the market, while offering a 7.2% dividend yield. Profitability is stellar with a 34.5% net margin and 86.6% gross margin, generating $9.07B in annual FCF to support shareholder returns. However, the stock trades near its 52-week high, limiting near-term capital appreciation potential, and analyst sentiment is mixed with no clear consensus target, reflecting the high uncertainty.
The two biggest risks that could invalidate this Hold thesis are: 1) A faster-than-expected decline in combustible volumes pressuring earnings and threatening dividend coverage, and 2) A rise in interest rates increasing the cost of servicing its substantial debt. This Hold would upgrade to a Buy if the price corrected meaningfully below $65 (offering a higher yield) and leverage metrics showed sustained improvement. It would downgrade to a Sell if quarterly cigarette shipment declines accelerated beyond mid-single digits or if free cash flow coverage of the dividend deteriorated. On balance, the stock appears fairly valued relative to its own history and the sector, pricing in both its robust cash generation and significant transition risks.
Sign up to view all
MO 12-Month Price Forecast
Altria is a stalwart income generator trapped in a declining industry. The 60% probability Base Case reflects the most likely path: the company will continue to milk its cash-cow cigarette business to fund its dividend and speculative investments, resulting in sideways trading. The high dividend yield and low beta make it a defensive income hold, not a growth investment. The stance would turn bullish only on a significant price pullback that boosts the yield above 8% or clear evidence that smoke-free products are becoming profit contributors. It would turn bearish on any indication of dividend risk, such as a consecutive quarterly earnings miss or a rise in the payout ratio above 110%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Altria's 12-month outlook, with a consensus price target around $91.25 and implied upside of +30.0% versus the current price.
Average Target
$91.25
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$56 - $91
Analyst target range
Analyst coverage is limited with only 6 analysts, and the consensus sentiment appears mixed given recent actions include both 'Buy' and 'Underweight' ratings. The average target price is not provided in the data, so the implied upside or downside cannot be calculated; however, the recent institutional ratings show a lack of strong directional conviction, with firms like UBS maintaining a 'Buy' while Barclays holds an 'Underweight'. The wide dispersion in analyst views, from 'Buy' to 'Underweight', signals high uncertainty regarding the company's ability to successfully transition its business model away from declining combustible products while maintaining its generous dividend, leading to a lack of clear consensus and potentially higher volatility due to this narrative divergence.
Bulls vs Bears: MO Investment Factors
The evidence presents a classic high-yield, value-trap dichotomy. The bull case is anchored in undeniable financial strength: exceptional 34.5% net margins, $9.1B in annual FCF, and a defensive 7.2% yield at a reasonable forward P/E of 12.2x. The bear case highlights severe structural risks: a leveraged balance sheet (D/E of -7.34), secular volume declines, and an uncertain transition to smoke-free products. Currently, the bull side has stronger evidence for income-focused investors, as the cash generation supporting the dividend is concrete and current. The single most important tension in the investment debate is whether Altria's immense cash flows from its declining legacy business can sustainably fund its dividend and successfully pivot to new growth categories before the debt burden becomes unsustainable.
Bullish
- Exceptional Profitability & Cash Flow: Altria's business model generates immense profitability, with a trailing net margin of 34.5% and a gross margin of 86.6%. This translates into robust free cash flow of $9.07 billion TTM, which fully funds its high dividend.
- High Dividend Yield of 7.2%: The stock offers a compelling 7.2% dividend yield, significantly above the market average. This is supported by a payout ratio of approximately 100%, indicating the dividend is currently covered by earnings, providing a strong income stream.
- Defensive Low-Beta Profile: With a beta of 0.50, MO is roughly 50% less volatile than the S&P 500. This defensive characteristic, combined with its 20% price gain over the past year, offers a rare combination of stability and capital appreciation in a volatile market.
- Undervalued on Forward Earnings: The stock trades at a forward P/E of 12.2x, which is a discount to the broader market and near the middle of its own historical range (5.2x to 20x+). This suggests the stock is not expensive relative to its earnings power.
Bearish
- Severe Balance Sheet Leverage: The company carries a massive debt burden, reflected in a negative Debt-to-Equity ratio of -7.34 and a weak Current Ratio of 0.61. This high leverage limits financial flexibility and increases risk if cash flows falter.
- Secular Decline in Core Business: The core combustible tobacco business faces persistent volume declines, a long-term structural headwind. The company's future depends on the uncertain success of its smoke-free investments (NJOY, Cronos), which have yet to prove they can replace lost cigarette profits.
- Analyst Uncertainty & Lack of Conviction: Analyst coverage is limited and mixed, with ratings ranging from 'Buy' to 'Underweight'. This wide dispersion signals high uncertainty about the company's transition and a lack of clear consensus, which can lead to higher volatility.
- Technical Overextension Near 52-Week High: The stock is trading at 96% of its 52-week high of $74.56 after a 20% rally. This suggests the positive momentum may be overextended in the short term, increasing vulnerability to a pullback, especially given recent consolidation signs.
MO Technical Analysis
The stock is in a sustained uptrend, having gained 20.06% over the past year, and is currently trading near the top of its 52-week range, at approximately 96% of the 52-week high of $74.56, indicating strong momentum but also potential overextension. Recent short-term momentum is positive but shows signs of consolidation, with a 5.97% gain over the last 3 months and a 0.56% gain over the past month, suggesting the powerful rally from early 2026 may be pausing. The stock exhibits low market volatility with a beta of 0.50, implying it is roughly 50% less volatile than the broader market, which is characteristic of a defensive consumer staple. Key technical support is at the 52-week low of $54.70, while immediate resistance is at the recent high of $74.56; a decisive breakout above this level would signal a continuation of the bullish trend, whereas a failure could lead to a test of support near the $65-$68 consolidation zone from March-April 2026.
Beta
0.50
0.50x market volatility
Max Drawdown
-19.1%
Largest decline past year
52-Week Range
$55-$75
Price range past year
Annual Return
+19.4%
Cumulative gain past year
| Period | MO Return | S&P 500 |
|---|---|---|
| 1m | -4.0% | +1.5% |
| 3m | +7.8% | +13.4% |
| 6m | +20.2% | +10.9% |
| 1y | +19.4% | +24.5% |
| ytd | +22.5% | +10.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MO Fundamental Analysis
Revenue growth is modest but positive, with Q4 2025 revenue of $5.85 billion representing a 14.5% year-over-year increase, though this was boosted by pricing power and the NJOY acquisition, as the core business faces volume declines. The company is highly profitable with strong margins, evidenced by a net income of $1.12 billion in Q4 2025 and a trailing twelve-month net margin of 34.5%, supported by a robust gross margin of 86.6% that reflects its pricing power in addictive products. Altria generates substantial cash flow, with trailing free cash flow of $9.07 billion, supporting its high dividend yield of 7.2%, but its balance sheet shows significant leverage with a negative debt-to-equity ratio of -7.34 and a weak current ratio of 0.61, indicating a heavy debt load and limited short-term liquidity which is a notable financial risk.
Quarterly Revenue
$5.8B
2025-12
Revenue YoY Growth
+0.14%
YoY Comparison
Gross Margin
+0.62%
Latest Quarter
Free Cash Flow
$9.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MO Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is 13.9x, while the forward PE is lower at 12.2x, indicating the market expects modest earnings growth. Compared to sector averages, Altria's trailing PE of 13.9x trades at a discount to the broader market, which is typical for a tobacco company facing secular headwinds, though its Price-to-Sales ratio of 4.8x is elevated relative to some staples, reflecting its high margins. Historically, the stock's own trailing PE has fluctuated significantly, from a low near 5.2x in mid-2024 to highs above 20x; the current 13.9x is in the middle of this range, suggesting the stock is neither historically cheap nor expensive, balancing its high yield against growth challenges.
PE
13.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -8x~81x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are centered on extreme leverage and cash flow concentration. The negative Debt-to-Equity ratio of -7.34 indicates shareholder equity has been eroded by significant debt, constraining strategic optionality. A weak Current Ratio of 0.61 signals potential liquidity strain in meeting short-term obligations. The dividend, with a payout ratio near 100%, is fully reliant on maintaining current profit levels; any earnings miss could force a painful cut. Revenue, while growing 14.5% YoY in Q4 2025, remains heavily dependent on cigarette pricing to offset volume declines, creating a fragile growth model.
Market & Competitive Risks stem from its premium valuation on sales and existential business model threats. The Price-to-Sales ratio of 4.8x is elevated for a company in a declining industry, implying the market prices in stability that may not persist. The core product faces relentless secular decline, increased regulation, and social stigma. Competitive disruption from next-generation nicotine products and cannabis remains a constant threat, as Altria's investments in NJOY and Cronos are unproven and capital-intensive. The stock's low beta of 0.50 offers defensive characteristics but does not immunize it from sector-specific de-rating if the decline narrative accelerates.
Worst-Case Scenario involves a 'perfect storm' where accelerated cigarette volume decline coincides with failed smoke-free investments, leading to an earnings shortfall. This could trigger a dividend cut, a loss of income-focused investors, and a credit rating downgrade that exacerbates refinancing costs for its heavy debt load. The chain reaction could see the stock re-test its 52-week low of $54.70, representing a potential downside of approximately -24% from the current price of ~$71.94. A more severe bear case, factoring in a multiple compression towards its historical low P/E near 5x, could imply even greater losses, though the high yield may provide a floor.
FAQ
The key risks are, in order of severity: 1) Financial Risk: Extreme balance sheet leverage with a Debt-to-Equity of -7.34 and weak liquidity (Current Ratio of 0.61) limits flexibility and increases vulnerability to rising rates. 2) Business Model Risk: Secular decline in cigarette volumes is a permanent headwind, requiring constant price hikes that may have limits. 3) Dividend Sustainability Risk: The payout ratio is near 100%, leaving no cushion; an earnings miss could force a cut, devastating the stock price. 4) Transition/Execution Risk: Investments in NJOY and Cronos are capital-intensive and unproven, with a high likelihood of failing to offset core profit declines.
The 12-month forecast is a range-bound outcome with a neutral bias. The Base Case (60% probability) sees the stock trading between $68 and $75, as stable earnings from pricing power support the dividend, but growth concerns cap multiple expansion. The Bull Case (25% probability) targets $78 to $85, requiring successful execution in smoke-free products and P/E expansion. The Bear Case (15% probability) sees a drop to $55-$65 on accelerated volume declines or dividend concerns. The most likely scenario is the Base Case, as it assumes the continuation of current trends: managed decline in cigarettes, stable cash flow, and a secure but unexciting dividend.
MO appears fairly valued relative to its own history and risk profile. Its forward P/E of 12.2x is a discount to the broader market but reasonable for a company facing secular decline. Historically, its trailing P/E has ranged from ~5.2x to over 20x, placing the current 13.9x near the middle. The Price-to-Sales ratio of 4.8x is elevated, reflecting its high margins. The valuation implies the market is paying a fair price for its current cash flows but assigns little to no value to its smoke-free transition efforts. It is not cheap enough to be considered deeply undervalued, nor expensive enough to be a clear sell, hence the 'fairly valued' assessment.
MO is a good buy only for a specific type of investor: one seeking high current income who understands and accepts the significant long-term risks. The 7.2% dividend yield is compelling and currently covered by earnings, supported by robust 34.5% net margins. However, the stock is not a good buy for growth-oriented investors, as its core business is in secular decline, and its balance sheet carries heavy leverage (Debt-to-Equity of -7.34). At its current price near 52-week highs, the margin of safety is thin. It becomes a more attractive buy on a pullback to the mid-$60s, which would push the yield above 8% and provide a better risk/reward entry point.
MO is primarily suitable as a long-term holding for income investors, not for short-term trading. Its low beta of 0.50 means it has low correlation with market swings, reducing its appeal for short-term momentum trades. The investment thesis is based on collecting the high, compounding dividend over years. However, the long-term horizon carries the risk that the business erosion eventually overwhelms the dividend model. A minimum holding period of 3-5 years is suggested to realize the benefits of dividend income, but investors must actively monitor the dividend coverage and volume trends quarterly. It is not suitable for short-term investors seeking capital appreciation.
